ABL Diagnostics

ABL Diagnostics S.A. is a Euronext-listed leader in targeted molecular genotyping for infectious diseases. The company has built a commercial, revenue-generating business around its proprietary DeepChek® platform, which enables precise pathogen characterization critical for managing drug resistance and personalizing treatment in HIV, HCV, TB, and beyond. Its strategy leverages a complete product portfolio—from UltraGene® RT-PCR and specimen collection kits to digital analysis software—to serve clinical and research labs globally through a direct and distributor network. Recent achievements include expanding its portfolio into HPV mRNA genotyping and securing exclusive distribution in key markets like Japan.

The DeepChek® platform provides targeted genotyping assays for infectious diseases using both Sanger and Next-Generation Sequencing (NGS), enabling precise identification of drug resistance mutations and viral variants with high sensitivity for low-frequency quasispecies.

ABL competes with large diversified diagnostics firms (e.g., Abbott, Roche) and specialized players in genotyping. Its differentiation lies in its targeted NGS expertise, integrated software ecosystem, and a broad portfolio of CE-IVD assays focused on microbiology, allowing for detailed resistance profiling that simpler PCR tests cannot provide.